Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19690428 | 0.88 | RAB9A (0.46) | MAPTALDH1A1RAB9ALMNAPOLB | |
| SCHEMBL19690305 | 0.83 | MAPT (0.45) | CYP3A4MAPTALDH1A1RAB9ALMNA | |
| SCHEMBL19690481 | 0.79 | RAB9A (0.56) | MAPTALDH1A1RAB9ALMNAPOLB | |
| SCHEMBL19690296 | 0.79 | RAB9A (0.56) | MAPTALDH1A1RAB9ALMNAPOLB | |
| SCHEMBL2892379 | 0.77 | MAPT (0.55) | TSHRMAPTALDH1A1RAB9ALMNA | |
| SCHEMBL19690307 | 0.75 | LMNA (0.46) | CYP3A4MAPTALDH1A1RAB9ALMNA | |
| SCHEMBL19690477 | 0.75 | LMNA (0.46) | CYP3A4MAPTALDH1A1RAB9ALMNA | |
| SCHEMBL939398 | 0.74 | ALDH1A1 (0.68) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL21031716 | 0.73 | ALDH1A1 (0.67) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL16599621 | 0.67 | TSHR (0.52) | TSHRCYP3A4MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858900-B2 | Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives | OCUTERRA THERAPEUTICS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20170355679-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | SCIFLUOR LIFE SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355679-A1 | FLUORINATED 2-AMINO-4-(SUBSTITUTED AMINO)PHENYL CARBAMATE DERIVATIVES | KCNQ2, KCNQ1, KCNQ3 | TSHR 3251/4885CYP3A4 929/4885MAPT 2123/4885 |
| US-11858900-B2 | Fluorinated 2-amino-4-(substituted amino)phenyl carbamate derivatives | KCNQ2, KCNQ1, KCNQ3 | TSHR 3251/4885CYP3A4 929/4885MAPT 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.